Clinical trials: Invasive Carcinoma
Muscle-invasive Bladder Urothelial Carcinoma
A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer
This is a prospective, open-label, single-center, single-arm clinical study. Plans to enroll 45 MIBC patients with clinical stage T2-T4aN0M0 and HER2-positive (IHC 1+/2+/3+) status.
- Trial name
- NCT07279597
- Testing
- RC48-ADC + Toripalimab
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Bladder Cancer
Bladder Tumor Biopsy Study to Improve Preoperative Determination of Stage and Grade
To assess whether the addition of a bladder tumor biopsy improves the level of agreement between the pretreatment endoscopic impression and the final postoperative pathology determination of stage and grade in non-muscle-invasive…
- Trial name
- NCT02992990
- Testing
- Bladder tumor biopsy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Baylor College of Medicine
Clear Cell Renal Cell Carcinoma
89Zr-DFO-girentuximab Expanded Access Program (EAP)
The purpose of this Expanded Access Program (EAP) is to enable the use of 89Zr-DFO-girentuximab with positron emission tomography/computed tomography (PET/CT) imaging to non-invasively detect carbonic anhydrase 9…
- Trial name
- NCT06090331
- Testing
- 89Zr-DFO-girentuximab
- Where
- 22 sites in United States
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Pancreatic Carcinoma, Surgery
The Comparision of Minimally-invasive and Open Pancreaticoduodenectomy for Pancreatic Cancer
Minimally invasive pancreaticoduodenectomy remains one of the most challenging abdominal procedures. Safety and feasibility remain controversial when comparing minimally-invasive with open pancreaticoduodenectomy, especially for…
- Trial name
- MIOPP (NCT03747588)
- Testing
- Minimally-invasive pancreaticoduodenectomy, Open pancreaticoduodenectomy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer
Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer
RATIONALE: Radiation therapy may kill any tumor cells remaining after surgery. PURPOSE: Phase I/II trial to study the effectiveness of brachytherapy in treating women who have stage I or stage II breast cancer.
- Trial name
- NCT00002873
- Testing
- brachytherapy
- Where
- 232 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Gastric Cancer, Chemotherapy Effect
Neo-adjuvant Chemotherapy Evluation in Gastric Cancer Patients Based on Circulating Exosomal LncRNA-GC1
The investigators hope that through the analysis and research to find determine whether lncRNA-GC1 could serve as a non-invasive biomarker for monitoring the neo-adjuvant chemotherapy response for personalized medicine for…
- Trial name
- NCT05647941
- Testing
- Detection of levels of circulating EV-derived lncRNA-GC1
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Chinese PLA General Hospital
Non-Small Cell Lung Cancer
ITTACA (Immunotherapy Time Teller for Advanced Lung Cancer)
Immunotherapy is a relatively new treatment that uses patients' own immune systems to fight diseases, particularly cancers. Recent studies suggest that the effectiveness of immunotherapy in cancer treatment may depend on the time…
- Trial name
- ITTACA (NCT07661251)
- Volunteers
- 60 people
- Sponsor
- Laura Longshaw
Bladder Cancer
Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC
This study assesses the effect of sequential radiation and durvalumab immunotherapy given as treatment prior to surgery with radical cystectomy for bladder cancer.
- Trial name
- RADIANT (NCT04543110)
- Testing
- Durvalumab, Immune Modulating Radiation
- Where
- 4 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Ottawa Hospital Research Institute
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
This phase Ib/II trial studies the side effects, best dose, and effectiveness of enfortumab vedotin (EV) in combination with pembrolizumab and radiation therapy for treating patients with muscle invasive bladder cancer.
- Conditions
- Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Trial name
- NCT06470282
- Testing
- Enfortumab Vedotin, Pembrolizumab, Intensity Modulated Radiation Therapy (IMRT)
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of California, San Francisco
Bladder Cancer, NMIBC
Age and Bladder Cancer Outcomes After BCG Treatment: A Multicenter Study
This study investigates whether a patient's age affects the outcomes of Bacillus Calmette-Guérin (BCG) treatment for high-grade bladder cancer.
- Trial name
- IATREP_NMIBC (NCT07798479)
- Testing
- Intravesical Bcg
- Volunteers
- 64 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Delayed Gastric Conduit Emtpying (DGCE), Minimally-invasive Esophagectomy
Balloon Dilation in Patients Undergoing Minimally Invasive Ivor Lewis Esophagectomy and Its Effect on Reducing DGCE
Background: Esophageal carcinoma ranks among the most common and lethal cancers worldwide. Minimally invasive esophagectomy is the standard curative treatment, but postoperative delayed gastric conduit emptying (DGCE) remains a…
- Trial name
- WIDE (NCT07355374)
- Testing
- endoscopic plyoric balloon dilatation performed by experienced gastroenterologists
- Where
- Switzerland
- Volunteers
- 116 people
- Sponsor
- University Hospital, Basel, Switzerland
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
This phase IIB trial studies how well enzalutamide and paclitaxel before surgery works in treating patients with stage I-III androgen receptor-positive triple-negative breast cancer.
- Conditions
- Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7
- Trial name
- NCT02689427
- Testing
- Axillary Lymph Node Dissection, Enzalutamide, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
NMIBC
ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
This expanded access protocol is designed to provide Recombinant Mycobacterium BCG (rMBCG) to patients with Non-muscle invasive bladder cancer (NMIBC) who are eligible to receive TICE® BCG, may benefit from its use, and who are…
- Trial name
- NCT06810141
- Testing
- rMBCG
- Where
- 66 sites in United States
- Sponsor
- ImmunityBio, Inc.
Urothelial Cancer, Urinary Bladder Neoplasms
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer.
- Trial name
- NCT07566156
- Testing
- Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy
- Where
- 29 sites in United States, Canada and 2 more
- Volunteers
- 390 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Breast Adenocarcinoma, HER2/Neu Negative
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
This randomized phase III trial studies how well eribulin mesylate or paclitaxel work as first- or second-line therapy in treating patients with stage IIIC-IV breast cancer that has come back.
- Conditions
- Breast Adenocarcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7
- Trial name
- NCT02037529
- Testing
- Eribulin Mesylate, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 39 sites in United States
- Volunteers
- 201 people
- Sponsor
- Academic and Community Cancer Research United
Tubular Breast Cancer, Mucinous Breast Cancer
Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women
The investigators hypotheses that paclitaxel combined with cisplatin in a weekly-based regimen as adjuvant chemotherapy is more effective for high risk, HER2 negative breast cancer .
- Conditions
- Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Duct Carcinoma of Breast
- Trial name
- NCT03201861
- Testing
- Paclitaxel, Cisplatin, EC to docetaxel or paclitaxel
- Where
- China
- Volunteers
- 762 people
- Sponsor
- RenJi Hospital
Non-muscle Invasive Bladder Cancer
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
The purpose of this study is to test the safety of the study drug 2141-V11 in people whose NMIBC did not respond to standard treatment, and who will not have the standard surgical procedure to remove the bladder.
- Trial name
- NCT05126472
- Testing
- anti-CD40 antibody 2141-V11, Intravesical Gemcitabine, Intravesical Gemcitabine with anti-CD40 antibody 2141-V11
- Where
- 7 sites in United States
- Volunteers
- 115 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Node-positive Breast Cancer
Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer
Single-arm, phase 2 study evaluating hypofractionated irradiation of breast and regional nodes in women with breast cancer. Patients will be grouped in 3 surgery-related treatment groups: 1) An intact breast following lumpectomy…
- Conditions
- Breast Cancer, Node-positive Breast Cancer, Breast Adenocarcinoma, Invasive Breast Carcinoma
- Trial name
- NCT02515110
- Testing
- External Beam Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 137 people
- Sponsor
- Virginia Commonwealth University
Ductal Carcinoma In Situ, Invasive Breast Cancer
The Prone Breast Radiation Therapy Trial
Participants undergoing radiation after breast conserving surgery for an early breast cancer (either Ductal Carcinoma In Situ (DCIS), or Early Stage Invasive breast cancer), and are at increased risk of developing a skin reaction…
- Trial name
- NCT01815476
- Testing
- Radiation Therapy Positioning Intervention
- Where
- 2 sites in Canada
- Volunteers
- 378 people
- Sponsor
- Toronto Sunnybrook Regional Cancer Centre
Bladder Urothelial Carcinoma, TURBT
Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBC
Compare the therapeutic utility of SPIES assisted TURB with WLI assisted TURB in patients with non-muscle invasive bladder cancer.
- Conditions
- Bladder Urothelial Carcinoma, TURBT, Bladder Neoplasm, Cystoscopy
- Trial name
- NCT03138824
- Testing
- SPIES assisted TURBT, WLI assisted TURBT
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.